Caprolactam Chemicals（507486）株式概要カプロラクタム・ケミカルズ社はインドで化学品の製造・販売を行っている。 詳細507486 ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績3/6財務の健全性2/6配当金0/6報酬株価収益率（ 12.5 x） Indian市場（ 23.4 x）を下回っています。今年は黒字化を達成 リスク分析負債は営業キャッシュフローで十分にカバーされていない 意味のある時価総額がありません ( ₹221M )意味のある収益がありません ( ₹106M )すべてのリスクチェックを見る507486 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW491,361 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA491,361 investors already sharing narrativesYour Fair Value₹Current Price₹48.0010.0% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-13m185m2016201920222025202620282031Revenue ₹185.2mEarnings ₹30.9mAdvancedSet Fair ValueView all narrativesCaprolactam Chemicals Limited 競合他社Haryana Leather ChemicalsSymbol: BSE:524080Market cap: ₹304.3mUnilex Colours and ChemicalsSymbol: NSEI:UNILEXMarket cap: ₹347.2mArunaya OrganicsSymbol: NSEI:ARUNAYAMarket cap: ₹280.6mGujarat PetrosyntheseSymbol: BSE:506858Market cap: ₹328.3m価格と性能株価の高値、安値、推移の概要Caprolactam Chemicals過去の株価現在の株価₹48.0052週高値₹81.0052週安値₹38.10ベータ0.301ヶ月の変化7.36%3ヶ月変化3.07%1年変化17.07%3年間の変化-18.64%5年間の変化-33.52%IPOからの変化-4.00%最新ニュースValuation Update With 7 Day Price Move • Jul 09Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹51.50, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 18% over the past three years.Reported Earnings • Jun 02Full year 2026 earnings released: EPS: ₹3.83 (vs ₹1.54 loss in FY 2025)Full year 2026 results: EPS: ₹3.83 (up from ₹1.54 loss in FY 2025). Revenue: ₹105.9m (up 57% from FY 2025). Net income: ₹17.6m (up ₹24.7m from FY 2025). Profit margin: 17% (up from net loss in FY 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.お知らせ • May 06Caprolactam Chemicals Limited to Report Q4, 2026 Results on May 30, 2026Caprolactam Chemicals Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026New Risk • Mar 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings have declined by 5.5% per year over the past 5 years. Revenue is less than US$1m (₹88m revenue, or US$961k). Market cap is less than US$10m (₹301.5m market cap, or US$3.28m).お知らせ • Jan 27Caprolactam Chemicals Limited to Report Q3, 2026 Results on Feb 13, 2026Caprolactam Chemicals Limited announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Earnings have declined by 5.5% per year over the past 5 years. Revenue is less than US$1m (₹88m revenue, or US$982k). Market cap is less than US$10m (₹291.0m market cap, or US$3.24m). Minor Risk Share price has been volatile over the past 3 months (7.0% average weekly change).最新情報をもっと見るRecent updatesValuation Update With 7 Day Price Move • Jul 09Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹51.50, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 18% over the past three years.Reported Earnings • Jun 02Full year 2026 earnings released: EPS: ₹3.83 (vs ₹1.54 loss in FY 2025)Full year 2026 results: EPS: ₹3.83 (up from ₹1.54 loss in FY 2025). Revenue: ₹105.9m (up 57% from FY 2025). Net income: ₹17.6m (up ₹24.7m from FY 2025). Profit margin: 17% (up from net loss in FY 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.お知らせ • May 06Caprolactam Chemicals Limited to Report Q4, 2026 Results on May 30, 2026Caprolactam Chemicals Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026New Risk • Mar 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings have declined by 5.5% per year over the past 5 years. Revenue is less than US$1m (₹88m revenue, or US$961k). Market cap is less than US$10m (₹301.5m market cap, or US$3.28m).お知らせ • Jan 27Caprolactam Chemicals Limited to Report Q3, 2026 Results on Feb 13, 2026Caprolactam Chemicals Limited announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Earnings have declined by 5.5% per year over the past 5 years. Revenue is less than US$1m (₹88m revenue, or US$982k). Market cap is less than US$10m (₹291.0m market cap, or US$3.24m). Minor Risk Share price has been volatile over the past 3 months (7.0% average weekly change).New Risk • Nov 16New major risk - Revenue and earnings growthEarnings have declined by 5.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Earnings have declined by 5.5% per year over the past 5 years. Revenue is less than US$1m (₹89m revenue, or US$998k). Market cap is less than US$10m (₹220.4m market cap, or US$2.49m).Reported Earnings • Nov 16Second quarter 2026 earnings released: EPS: ₹0.27 (vs ₹0.09 in 2Q 2025)Second quarter 2026 results: EPS: ₹0.27 (up from ₹0.09 in 2Q 2025). Revenue: ₹23.9m (up 39% from 2Q 2025). Net income: ₹1.26m (up 215% from 2Q 2025). Profit margin: 5.3% (up from 2.3% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.お知らせ • Oct 24Caprolactam Chemicals Limited to Report First Half, 2026 Results on Nov 14, 2025Caprolactam Chemicals Limited announced that they will report first half, 2026 results on Nov 14, 2025お知らせ • Aug 18Caprolactam Chemicals Limited, Annual General Meeting, Sep 25, 2025Caprolactam Chemicals Limited, Annual General Meeting, Sep 25, 2025, at 10:30 Indian Standard Time.Reported Earnings • Aug 16First quarter 2026 earnings released: EPS: ₹0.79 (vs ₹0.58 loss in 1Q 2025)First quarter 2026 results: EPS: ₹0.79 (up from ₹0.58 loss in 1Q 2025). Revenue: ₹25.7m (up 128% from 1Q 2025). Net income: ₹3.62m (up ₹6.28m from 1Q 2025). Profit margin: 14% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.お知らせ • Aug 09Caprolactam Chemicals Limited to Report Q1, 2026 Results on Aug 14, 2025Caprolactam Chemicals Limited announced that they will report Q1, 2026 results on Aug 14, 2025New Risk • Jun 02New major risk - Revenue and earnings growthEarnings have declined by 1.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 1.3% per year over the past 5 years. Revenue is less than US$1m (₹67m revenue, or US$790k). Market cap is less than US$10m (₹187.7m market cap, or US$2.20m).Reported Earnings • Jun 02Full year 2025 earnings released: ₹1.54 loss per share (vs ₹0.43 profit in FY 2024)Full year 2025 results: ₹1.54 loss per share (down from ₹0.43 profit in FY 2024). Revenue: ₹67.5m (down 3.0% from FY 2024). Net loss: ₹7.09m (down 459% from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.お知らせ • May 17Caprolactam Chemicals Limited to Report Q4, 2025 Results on May 30, 2025Caprolactam Chemicals Limited announced that they will report Q4, 2025 results on May 30, 2025New Risk • Apr 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.0x net interest cover). Earnings have declined by 5.9% per year over the past 5 years. Revenue is less than US$1m (₹66m revenue, or US$771k). Market cap is less than US$10m (₹188.0m market cap, or US$2.21m). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).New Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.0x net interest cover). Share price has been highly volatile over the past 3 months (9.5% average weekly change). Earnings have declined by 5.9% per year over the past 5 years. Revenue is less than US$1m (₹66m revenue, or US$753k). Market cap is less than US$10m (₹190.0m market cap, or US$2.18m).Reported Earnings • Feb 16Third quarter 2025 earnings released: ₹0.07 loss per share (vs ₹0.35 loss in 3Q 2024)Third quarter 2025 results: ₹0.07 loss per share (improved from ₹0.35 loss in 3Q 2024). Revenue: ₹23.0m (up 55% from 3Q 2024). Net loss: ₹317.0k (loss narrowed 81% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Jan 28Caprolactam Chemicals Limited to Report Q3, 2025 Results on Feb 14, 2025Caprolactam Chemicals Limited announced that they will report Q3, 2025 results on Feb 14, 2025New Risk • Dec 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m (₹58m revenue, or US$674k). Market cap is less than US$10m (₹287.0m market cap, or US$3.36m).Reported Earnings • Nov 13Second quarter 2025 earnings released: EPS: ₹0.09 (vs ₹0.12 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹0.09 (up from ₹0.12 loss in 2Q 2024). Revenue: ₹17.1m (down 13% from 2Q 2024). Net income: ₹399.0k (up ₹959.0k from 2Q 2024). Profit margin: 2.3% (up from net loss in 2Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Nov 05Caprolactam Chemicals Limited to Report Q2, 2025 Results on Nov 12, 2024Caprolactam Chemicals Limited announced that they will report Q2, 2025 results on Nov 12, 2024お知らせ • Sep 24Caprolactam Chemicals Limited Announces Appointment of DirectorsCaprolactam Chemicals Limited announced that at its AGM held on September 24, 2024, shareholders approved the appointment of Mr. Viren Jaysukhlal lasani as lndependent Director and Mr. Kamlesh Damji Joisher as Independent Director, not liable to retire by rotation, for the first term of 5 years.お知らせ • Aug 29Caprolactam Chemicals Limited, Annual General Meeting, Sep 24, 2024Caprolactam Chemicals Limited, Annual General Meeting, Sep 24, 2024, at 11:30 Indian Standard Time.Reported Earnings • Aug 14First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₹11.2m (down 44% from 1Q 2024). Net loss: ₹2.66m (down 319% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • Jul 18Caprolactam Chemicals Limited to Report Q1, 2025 Results on Aug 12, 2024Caprolactam Chemicals Limited announced that they will report Q1, 2025 results on Aug 12, 2024Reported Earnings • May 29Full year 2024 earnings released: EPS: ₹0.43 (vs ₹5.54 in FY 2023)Full year 2024 results: EPS: ₹0.43 (down from ₹5.54 in FY 2023). Revenue: ₹71.4m (down 28% from FY 2023). Net income: ₹1.97m (down 92% from FY 2023). Profit margin: 2.8% (down from 26% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Reported Earnings • Feb 10Third quarter 2024 earnings released: ₹0.35 loss per share (vs ₹1.60 profit in 3Q 2023)Third quarter 2024 results: ₹0.35 loss per share (down from ₹1.60 profit in 3Q 2023). Revenue: ₹14.9m (down 37% from 3Q 2023). Net loss: ₹1.63m (down 122% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 18Caprolactam Chemicals Limited to Report Nine Months, 2024 Results on Feb 09, 2024Caprolactam Chemicals Limited announced that they will report nine months, 2024 results on Feb 09, 2024New Risk • Nov 20New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.8x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.8x net interest cover). Market cap is less than US$10m (₹293.8m market cap, or US$3.53m). Minor Risk Revenue is less than US$5m (₹86m revenue, or US$1.0m).お知らせ • Nov 04Caprolactam Chemicals Limited to Report Q2, 2024 Results on Nov 11, 2023Caprolactam Chemicals Limited announced that they will report Q2, 2024 results on Nov 11, 2023お知らせ • Sep 02Caprolactam Chemicals Limited, Annual General Meeting, Sep 25, 2023Caprolactam Chemicals Limited, Annual General Meeting, Sep 25, 2023, at 11:00 Indian Standard Time. Location: B/31, MIDC, Mahad, Distt. - Raigad. Maharashtra- 402302 Raigad Maharashtra India Agenda: To consider and adopt the Annual Audited Financial Statements of the Company for the financial year ended 315t March, 2023 together with the reports of the Board of Directors and Auditors thereon; and to consider other issues.お知らせ • Aug 03Caprolactam Chemicals Limited to Report Q1, 2024 Results on Aug 12, 2023Caprolactam Chemicals Limited announced that they will report Q1, 2024 results on Aug 12, 2023New Risk • Jul 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (15% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.9% average weekly change). High level of non-cash earnings (45% accrual ratio). Market cap is less than US$10m (₹278.2m market cap, or US$3.39m). Minor Risk Revenue is less than US$5m (₹98m revenue, or US$1.2m).Valuation Update With 7 Day Price Move • Jun 27Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹54.87, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 127% over the past three years.Reported Earnings • May 31Full year 2023 earnings released: EPS: ₹5.54 (vs ₹2.79 loss in FY 2022)Full year 2023 results: EPS: ₹5.54 (up from ₹2.79 loss in FY 2022). Revenue: ₹98.6m (up 376% from FY 2022). Net income: ₹25.5m (up ₹38.3m from FY 2022). Profit margin: 26% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year and the company’s share price has also increased by 43% per year.Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹54.69, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 186% over the past three years.Reported Earnings • Feb 16Third quarter 2023 earnings released: EPS: ₹1.60 (vs ₹1.76 loss in 3Q 2022)Third quarter 2023 results: EPS: ₹1.60 (up from ₹1.76 loss in 3Q 2022). Revenue: ₹23.7m (up ₹22.2m from 3Q 2022). Net income: ₹7.35m (up ₹15.4m from 3Q 2022). Profit margin: 31% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 59% per year, which means it is well ahead of earnings.お知らせ • Feb 02Caprolactam Chemicals Limited to Report First Half, 2023 Results on Feb 14, 2023Caprolactam Chemicals Limited announced that they will report first half, 2023 results on Feb 14, 2023Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Additional Independent Non-Executive Director Poonam Bhanushali was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 03Caprolactam Chemicals Limited to Report Q2, 2023 Results on Nov 14, 2022Caprolactam Chemicals Limited announced that they will report Q2, 2023 results on Nov 14, 2022Reported Earnings • Sep 04Full year 2022 earnings released: ₹2.79 loss per share (vs ₹1.41 profit in FY 2021)Full year 2022 results: ₹2.79 loss per share (down from ₹1.41 profit in FY 2021). Revenue: ₹24.7m (down 61% from FY 2021). Net loss: ₹12.8m (down 297% from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 176 percentage points per year, which is a significant difference in performance.お知らせ • Aug 07Caprolactam Chemicals Limited to Report Q1, 2023 Results on Aug 13, 2022Caprolactam Chemicals Limited announced that they will report Q1, 2023 results on Aug 13, 2022お知らせ • May 06Caprolactam Chemicals Limited to Report Q4, 2022 Results on May 30, 2022Caprolactam Chemicals Limited announced that they will report Q4, 2022 results on May 30, 2022Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Additional Independent Non-Executive Director Poonam Bhanushali was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 17Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: ₹1.76 loss per share (down from ₹1.94 profit in 3Q 2021). Revenue: ₹1.78m (down 93% from 3Q 2021). Net loss: ₹8.10m (down 191% from profit in 3Q 2021). Revenue was in line with analyst estimates.お知らせ • Feb 02Caprolactam Chemicals Limited to Report Q3, 2022 Results on Feb 14, 2022Caprolactam Chemicals Limited announced that they will report Q3, 2022 results on Feb 14, 2022Reported Earnings • Nov 18Second quarter 2022 earnings released: ₹0.75 loss per share (vs ₹0.49 profit in 2Q 2021)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹5.96m (down 59% from 2Q 2021). Net loss: ₹3.43m (down 252% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 89% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Aug 20Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹57.50, the stock trades at a trailing P/E ratio of 41x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 464% over the past three years.Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹68.80, the stock trades at a trailing P/E ratio of 48.7x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 568% over the past three years.Valuation Update With 7 Day Price Move • Jul 14Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹88.05, the stock trades at a trailing P/E ratio of 62.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 739% over the past three years.Reported Earnings • Jul 06Full year 2021 earnings released: EPS ₹1.41 (vs ₹2.07 in FY 2020)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹63.1m (down 3.1% from FY 2020). Net income: ₹6.51m (down 32% from FY 2020). Profit margin: 10% (down from 15% in FY 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 117% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • May 12Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹35.40, the stock trades at a trailing P/E ratio of 53.2x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 251% over the past three years.Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹35.90, the stock trades at a trailing P/E ratio of 53.9x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 256% over the past three years.Valuation Update With 7 Day Price Move • Mar 02Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹26.25, the stock is trading at a trailing P/E ratio of 39.4x, up from the previous P/E ratio of 33.9x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 135%.Is New 90 Day High Low • Mar 01New 90-day high: ₹25.00The company is up 41% from its price of ₹17.70 on 01 December 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹24.05, the stock is trading at a trailing P/E ratio of 36.1x, up from the previous P/E ratio of 28.5x. This compares to an average P/E of 18x in the Chemicals industry in India. Total returns to shareholders over the past three years are 95%.Is New 90 Day High Low • Feb 04New 90-day high: ₹20.90The company is up 31% from its price of ₹15.90 on 04 November 2020. The Indian market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period.Reported Earnings • Feb 03Third quarter 2021 earnings released: EPS ₹1.94 (vs ₹1.30 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹25.3m (up 28% from 3Q 2020). Net income: ₹8.92m (up 49% from 3Q 2020). Profit margin: 35% (up from 30% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 23Caprolactam Chemicals Limited to Report Q3, 2021 Results on Feb 02, 2021Caprolactam Chemicals Limited announced that they will report Q3, 2021 results on Feb 02, 2021Is New 90 Day High Low • Jan 07New 90-day high: ₹19.55The company is up 18% from its price of ₹16.60 on 09 October 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 23% over the same period.Reported Earnings • Nov 10Second quarter 2021 earnings released: EPS ₹0.49The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹14.6m (up 24% from 2Q 2020). Net income: ₹2.26m (up ₹2.44m from 2Q 2020). Profit margin: 15% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Sep 25New 90-day low: ₹15.55The company is down 29% from its price of ₹22.05 on 26 June 2020. The Indian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.お知らせ • Sep 13Caprolactam Chemicals Limited to Report Q1, 2021 Results on Aug 01, 2020Caprolactam Chemicals Limited announced that they will report Q1, 2021 results on Aug 01, 2020株主還元507486IN ChemicalsIN 市場7D-3.7%-1.5%-1.1%1Y17.1%-3.8%0.6%株主還元を見る業界別リターン: 507486過去 1 年間で-3.8 % の収益を上げたIndian Chemicals業界を上回りました。リターン対市場: 507486過去 1 年間で0.6 % の収益を上げたIndian市場を上回りました。価格変動Is 507486's price volatile compared to industry and market?507486 volatility507486 Average Weekly Movement7.3%Chemicals Industry Average Movement6.0%Market Average Movement6.0%10% most volatile stocks in IN Market9.0%10% least volatile stocks in IN Market3.7%安定した株価: 507486 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 507486の 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1988n/aZaver Bhanushaliwww.caprolactam.co.inカプロラクタム・ケミカルズ社はインドで化学品の製造・販売を行っている。また、関連業務サービスも提供している。以前はVamotiwala Chemicals Industries Limitedとして知られていたが、Caprolactam Chemicals Limitedに社名変更。カプロラクタム・ケミカルズは1988年に設立され、インドのマハドに拠点を置く。もっと見るCaprolactam Chemicals Limited 基礎のまとめCaprolactam Chemicals の収益と売上を時価総額と比較するとどうか。507486 基礎統計学時価総額₹220.80m収益（TTM）₹17.61m売上高(TTM)₹105.58m12.5xPER（株価収益率2.1xP/Sレシオ507486 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計507486 損益計算書（TTM）収益₹105.58m売上原価₹8.85m売上総利益₹96.73mその他の費用₹79.12m収益₹17.61m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）3.83グロス・マージン91.62%純利益率16.68%有利子負債／自己資本比率140.2%507486 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/29 11:37終値2026/07/29 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Caprolactam Chemicals Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Jul 09Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹51.50, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 18% over the past three years.
Reported Earnings • Jun 02Full year 2026 earnings released: EPS: ₹3.83 (vs ₹1.54 loss in FY 2025)Full year 2026 results: EPS: ₹3.83 (up from ₹1.54 loss in FY 2025). Revenue: ₹105.9m (up 57% from FY 2025). Net income: ₹17.6m (up ₹24.7m from FY 2025). Profit margin: 17% (up from net loss in FY 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
お知らせ • May 06Caprolactam Chemicals Limited to Report Q4, 2026 Results on May 30, 2026Caprolactam Chemicals Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
New Risk • Mar 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings have declined by 5.5% per year over the past 5 years. Revenue is less than US$1m (₹88m revenue, or US$961k). Market cap is less than US$10m (₹301.5m market cap, or US$3.28m).
お知らせ • Jan 27Caprolactam Chemicals Limited to Report Q3, 2026 Results on Feb 13, 2026Caprolactam Chemicals Limited announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Earnings have declined by 5.5% per year over the past 5 years. Revenue is less than US$1m (₹88m revenue, or US$982k). Market cap is less than US$10m (₹291.0m market cap, or US$3.24m). Minor Risk Share price has been volatile over the past 3 months (7.0% average weekly change).
Valuation Update With 7 Day Price Move • Jul 09Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹51.50, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 18% over the past three years.
Reported Earnings • Jun 02Full year 2026 earnings released: EPS: ₹3.83 (vs ₹1.54 loss in FY 2025)Full year 2026 results: EPS: ₹3.83 (up from ₹1.54 loss in FY 2025). Revenue: ₹105.9m (up 57% from FY 2025). Net income: ₹17.6m (up ₹24.7m from FY 2025). Profit margin: 17% (up from net loss in FY 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
お知らせ • May 06Caprolactam Chemicals Limited to Report Q4, 2026 Results on May 30, 2026Caprolactam Chemicals Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
New Risk • Mar 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings have declined by 5.5% per year over the past 5 years. Revenue is less than US$1m (₹88m revenue, or US$961k). Market cap is less than US$10m (₹301.5m market cap, or US$3.28m).
お知らせ • Jan 27Caprolactam Chemicals Limited to Report Q3, 2026 Results on Feb 13, 2026Caprolactam Chemicals Limited announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Earnings have declined by 5.5% per year over the past 5 years. Revenue is less than US$1m (₹88m revenue, or US$982k). Market cap is less than US$10m (₹291.0m market cap, or US$3.24m). Minor Risk Share price has been volatile over the past 3 months (7.0% average weekly change).
New Risk • Nov 16New major risk - Revenue and earnings growthEarnings have declined by 5.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Earnings have declined by 5.5% per year over the past 5 years. Revenue is less than US$1m (₹89m revenue, or US$998k). Market cap is less than US$10m (₹220.4m market cap, or US$2.49m).
Reported Earnings • Nov 16Second quarter 2026 earnings released: EPS: ₹0.27 (vs ₹0.09 in 2Q 2025)Second quarter 2026 results: EPS: ₹0.27 (up from ₹0.09 in 2Q 2025). Revenue: ₹23.9m (up 39% from 2Q 2025). Net income: ₹1.26m (up 215% from 2Q 2025). Profit margin: 5.3% (up from 2.3% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.
お知らせ • Oct 24Caprolactam Chemicals Limited to Report First Half, 2026 Results on Nov 14, 2025Caprolactam Chemicals Limited announced that they will report first half, 2026 results on Nov 14, 2025
お知らせ • Aug 18Caprolactam Chemicals Limited, Annual General Meeting, Sep 25, 2025Caprolactam Chemicals Limited, Annual General Meeting, Sep 25, 2025, at 10:30 Indian Standard Time.
Reported Earnings • Aug 16First quarter 2026 earnings released: EPS: ₹0.79 (vs ₹0.58 loss in 1Q 2025)First quarter 2026 results: EPS: ₹0.79 (up from ₹0.58 loss in 1Q 2025). Revenue: ₹25.7m (up 128% from 1Q 2025). Net income: ₹3.62m (up ₹6.28m from 1Q 2025). Profit margin: 14% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 09Caprolactam Chemicals Limited to Report Q1, 2026 Results on Aug 14, 2025Caprolactam Chemicals Limited announced that they will report Q1, 2026 results on Aug 14, 2025
New Risk • Jun 02New major risk - Revenue and earnings growthEarnings have declined by 1.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 1.3% per year over the past 5 years. Revenue is less than US$1m (₹67m revenue, or US$790k). Market cap is less than US$10m (₹187.7m market cap, or US$2.20m).
Reported Earnings • Jun 02Full year 2025 earnings released: ₹1.54 loss per share (vs ₹0.43 profit in FY 2024)Full year 2025 results: ₹1.54 loss per share (down from ₹0.43 profit in FY 2024). Revenue: ₹67.5m (down 3.0% from FY 2024). Net loss: ₹7.09m (down 459% from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
お知らせ • May 17Caprolactam Chemicals Limited to Report Q4, 2025 Results on May 30, 2025Caprolactam Chemicals Limited announced that they will report Q4, 2025 results on May 30, 2025
New Risk • Apr 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.0x net interest cover). Earnings have declined by 5.9% per year over the past 5 years. Revenue is less than US$1m (₹66m revenue, or US$771k). Market cap is less than US$10m (₹188.0m market cap, or US$2.21m). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).
New Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.0x net interest cover). Share price has been highly volatile over the past 3 months (9.5% average weekly change). Earnings have declined by 5.9% per year over the past 5 years. Revenue is less than US$1m (₹66m revenue, or US$753k). Market cap is less than US$10m (₹190.0m market cap, or US$2.18m).
Reported Earnings • Feb 16Third quarter 2025 earnings released: ₹0.07 loss per share (vs ₹0.35 loss in 3Q 2024)Third quarter 2025 results: ₹0.07 loss per share (improved from ₹0.35 loss in 3Q 2024). Revenue: ₹23.0m (up 55% from 3Q 2024). Net loss: ₹317.0k (loss narrowed 81% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Jan 28Caprolactam Chemicals Limited to Report Q3, 2025 Results on Feb 14, 2025Caprolactam Chemicals Limited announced that they will report Q3, 2025 results on Feb 14, 2025
New Risk • Dec 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m (₹58m revenue, or US$674k). Market cap is less than US$10m (₹287.0m market cap, or US$3.36m).
Reported Earnings • Nov 13Second quarter 2025 earnings released: EPS: ₹0.09 (vs ₹0.12 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹0.09 (up from ₹0.12 loss in 2Q 2024). Revenue: ₹17.1m (down 13% from 2Q 2024). Net income: ₹399.0k (up ₹959.0k from 2Q 2024). Profit margin: 2.3% (up from net loss in 2Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Nov 05Caprolactam Chemicals Limited to Report Q2, 2025 Results on Nov 12, 2024Caprolactam Chemicals Limited announced that they will report Q2, 2025 results on Nov 12, 2024
お知らせ • Sep 24Caprolactam Chemicals Limited Announces Appointment of DirectorsCaprolactam Chemicals Limited announced that at its AGM held on September 24, 2024, shareholders approved the appointment of Mr. Viren Jaysukhlal lasani as lndependent Director and Mr. Kamlesh Damji Joisher as Independent Director, not liable to retire by rotation, for the first term of 5 years.
お知らせ • Aug 29Caprolactam Chemicals Limited, Annual General Meeting, Sep 24, 2024Caprolactam Chemicals Limited, Annual General Meeting, Sep 24, 2024, at 11:30 Indian Standard Time.
Reported Earnings • Aug 14First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₹11.2m (down 44% from 1Q 2024). Net loss: ₹2.66m (down 319% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • Jul 18Caprolactam Chemicals Limited to Report Q1, 2025 Results on Aug 12, 2024Caprolactam Chemicals Limited announced that they will report Q1, 2025 results on Aug 12, 2024
Reported Earnings • May 29Full year 2024 earnings released: EPS: ₹0.43 (vs ₹5.54 in FY 2023)Full year 2024 results: EPS: ₹0.43 (down from ₹5.54 in FY 2023). Revenue: ₹71.4m (down 28% from FY 2023). Net income: ₹1.97m (down 92% from FY 2023). Profit margin: 2.8% (down from 26% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Reported Earnings • Feb 10Third quarter 2024 earnings released: ₹0.35 loss per share (vs ₹1.60 profit in 3Q 2023)Third quarter 2024 results: ₹0.35 loss per share (down from ₹1.60 profit in 3Q 2023). Revenue: ₹14.9m (down 37% from 3Q 2023). Net loss: ₹1.63m (down 122% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 18Caprolactam Chemicals Limited to Report Nine Months, 2024 Results on Feb 09, 2024Caprolactam Chemicals Limited announced that they will report nine months, 2024 results on Feb 09, 2024
New Risk • Nov 20New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.8x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.8x net interest cover). Market cap is less than US$10m (₹293.8m market cap, or US$3.53m). Minor Risk Revenue is less than US$5m (₹86m revenue, or US$1.0m).
お知らせ • Nov 04Caprolactam Chemicals Limited to Report Q2, 2024 Results on Nov 11, 2023Caprolactam Chemicals Limited announced that they will report Q2, 2024 results on Nov 11, 2023
お知らせ • Sep 02Caprolactam Chemicals Limited, Annual General Meeting, Sep 25, 2023Caprolactam Chemicals Limited, Annual General Meeting, Sep 25, 2023, at 11:00 Indian Standard Time. Location: B/31, MIDC, Mahad, Distt. - Raigad. Maharashtra- 402302 Raigad Maharashtra India Agenda: To consider and adopt the Annual Audited Financial Statements of the Company for the financial year ended 315t March, 2023 together with the reports of the Board of Directors and Auditors thereon; and to consider other issues.
お知らせ • Aug 03Caprolactam Chemicals Limited to Report Q1, 2024 Results on Aug 12, 2023Caprolactam Chemicals Limited announced that they will report Q1, 2024 results on Aug 12, 2023
New Risk • Jul 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (15% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.9% average weekly change). High level of non-cash earnings (45% accrual ratio). Market cap is less than US$10m (₹278.2m market cap, or US$3.39m). Minor Risk Revenue is less than US$5m (₹98m revenue, or US$1.2m).
Valuation Update With 7 Day Price Move • Jun 27Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹54.87, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 127% over the past three years.
Reported Earnings • May 31Full year 2023 earnings released: EPS: ₹5.54 (vs ₹2.79 loss in FY 2022)Full year 2023 results: EPS: ₹5.54 (up from ₹2.79 loss in FY 2022). Revenue: ₹98.6m (up 376% from FY 2022). Net income: ₹25.5m (up ₹38.3m from FY 2022). Profit margin: 26% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year and the company’s share price has also increased by 43% per year.
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹54.69, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 186% over the past three years.
Reported Earnings • Feb 16Third quarter 2023 earnings released: EPS: ₹1.60 (vs ₹1.76 loss in 3Q 2022)Third quarter 2023 results: EPS: ₹1.60 (up from ₹1.76 loss in 3Q 2022). Revenue: ₹23.7m (up ₹22.2m from 3Q 2022). Net income: ₹7.35m (up ₹15.4m from 3Q 2022). Profit margin: 31% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 59% per year, which means it is well ahead of earnings.
お知らせ • Feb 02Caprolactam Chemicals Limited to Report First Half, 2023 Results on Feb 14, 2023Caprolactam Chemicals Limited announced that they will report first half, 2023 results on Feb 14, 2023
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Additional Independent Non-Executive Director Poonam Bhanushali was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 03Caprolactam Chemicals Limited to Report Q2, 2023 Results on Nov 14, 2022Caprolactam Chemicals Limited announced that they will report Q2, 2023 results on Nov 14, 2022
Reported Earnings • Sep 04Full year 2022 earnings released: ₹2.79 loss per share (vs ₹1.41 profit in FY 2021)Full year 2022 results: ₹2.79 loss per share (down from ₹1.41 profit in FY 2021). Revenue: ₹24.7m (down 61% from FY 2021). Net loss: ₹12.8m (down 297% from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 176 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 07Caprolactam Chemicals Limited to Report Q1, 2023 Results on Aug 13, 2022Caprolactam Chemicals Limited announced that they will report Q1, 2023 results on Aug 13, 2022
お知らせ • May 06Caprolactam Chemicals Limited to Report Q4, 2022 Results on May 30, 2022Caprolactam Chemicals Limited announced that they will report Q4, 2022 results on May 30, 2022
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Additional Independent Non-Executive Director Poonam Bhanushali was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 17Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: ₹1.76 loss per share (down from ₹1.94 profit in 3Q 2021). Revenue: ₹1.78m (down 93% from 3Q 2021). Net loss: ₹8.10m (down 191% from profit in 3Q 2021). Revenue was in line with analyst estimates.
お知らせ • Feb 02Caprolactam Chemicals Limited to Report Q3, 2022 Results on Feb 14, 2022Caprolactam Chemicals Limited announced that they will report Q3, 2022 results on Feb 14, 2022
Reported Earnings • Nov 18Second quarter 2022 earnings released: ₹0.75 loss per share (vs ₹0.49 profit in 2Q 2021)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹5.96m (down 59% from 2Q 2021). Net loss: ₹3.43m (down 252% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 89% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Aug 20Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹57.50, the stock trades at a trailing P/E ratio of 41x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 464% over the past three years.
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹68.80, the stock trades at a trailing P/E ratio of 48.7x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 568% over the past three years.
Valuation Update With 7 Day Price Move • Jul 14Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹88.05, the stock trades at a trailing P/E ratio of 62.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 739% over the past three years.
Reported Earnings • Jul 06Full year 2021 earnings released: EPS ₹1.41 (vs ₹2.07 in FY 2020)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹63.1m (down 3.1% from FY 2020). Net income: ₹6.51m (down 32% from FY 2020). Profit margin: 10% (down from 15% in FY 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 117% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • May 12Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹35.40, the stock trades at a trailing P/E ratio of 53.2x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 251% over the past three years.
Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹35.90, the stock trades at a trailing P/E ratio of 53.9x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 256% over the past three years.
Valuation Update With 7 Day Price Move • Mar 02Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹26.25, the stock is trading at a trailing P/E ratio of 39.4x, up from the previous P/E ratio of 33.9x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 135%.
Is New 90 Day High Low • Mar 01New 90-day high: ₹25.00The company is up 41% from its price of ₹17.70 on 01 December 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹24.05, the stock is trading at a trailing P/E ratio of 36.1x, up from the previous P/E ratio of 28.5x. This compares to an average P/E of 18x in the Chemicals industry in India. Total returns to shareholders over the past three years are 95%.
Is New 90 Day High Low • Feb 04New 90-day high: ₹20.90The company is up 31% from its price of ₹15.90 on 04 November 2020. The Indian market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period.
Reported Earnings • Feb 03Third quarter 2021 earnings released: EPS ₹1.94 (vs ₹1.30 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹25.3m (up 28% from 3Q 2020). Net income: ₹8.92m (up 49% from 3Q 2020). Profit margin: 35% (up from 30% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 23Caprolactam Chemicals Limited to Report Q3, 2021 Results on Feb 02, 2021Caprolactam Chemicals Limited announced that they will report Q3, 2021 results on Feb 02, 2021
Is New 90 Day High Low • Jan 07New 90-day high: ₹19.55The company is up 18% from its price of ₹16.60 on 09 October 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 23% over the same period.
Reported Earnings • Nov 10Second quarter 2021 earnings released: EPS ₹0.49The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹14.6m (up 24% from 2Q 2020). Net income: ₹2.26m (up ₹2.44m from 2Q 2020). Profit margin: 15% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Sep 25New 90-day low: ₹15.55The company is down 29% from its price of ₹22.05 on 26 June 2020. The Indian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.
お知らせ • Sep 13Caprolactam Chemicals Limited to Report Q1, 2021 Results on Aug 01, 2020Caprolactam Chemicals Limited announced that they will report Q1, 2021 results on Aug 01, 2020
